New hope for kids with kidney disease: rituximab cuts relapse risk
NCT ID NCT07049172
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether rituximab, a medication that targets certain immune cells, could help children with a challenging form of nephrotic syndrome (a kidney disease) that keeps coming back. 91 children were split into two groups: one received rituximab plus special nursing care, the other received a standard drug (tacrolimus) plus the same care. The goal was to see which approach better prevented relapses and improved quality of life over 6 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME IN CHILDREN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wuhan Children's Hospital
Wuhan, Hubei, 430015, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could less steroid be just as good for kids with kidney disease?
- Ear-Zap therapy could spare kids from harsh kidney drugs
- Ear-Zap therapy could spare kids from steroid side effects
- Personalized trial matching could revolutionize kidney disease treatment
- New hope for kids with kidney disease: can dupilumab stop relapses?
- New study aims to measure swelling in kidney disease patients